Neutrophil infiltration plays a significant pathological role in inflammatory diseases. NADPH oxidase type 2 (NOX2) is a respiratory burst oxidase that generates large amounts of superoxide anion (O 2
Introduction
Leukocytes are major immune cells in the human circulatory system. Neutrophils are the predominant leukocytes for defense against pathogen invasion [1, 2] . However, neutrophils phagocytose pathogens and generate cytotoxic mediators that induce severe inflammatory responses [1, 3] . Overproduction of superoxide anion (O 2
•− ), a reactive oxygen species (ROS) precursor, from neutrophils can damage surrounding cells and result in inflammatory disorders and autoimmune diseases [3] [4] [5] .
NADPH oxidase type 2 (NOX2) is composed of six subunits and responsible for O 2 •− generation during respiratory burst. With stimulation, membrane-associated catalytic subunit, gp91 phox , assembles with other subunits, p22 phox , p47 phox , p67 phox , p40 phox , and Rac2, to form active NADPH oxidase in neutrophils [5, 6] . Prolonged and uncontrolled ROS generation by NOX2 is a crucial pathogenic factor in the pathogenesis of several inflammatory disorders and autoimmune diseases, such as arthritis, acute respiratory distress syndrome, or systemic lupus erythematosus [3, [7] [8] [9] . Importantly, pharmacological inhibition or deficiency of NOX2 can restrict inflammatory responses and [f]indol-9(4H)-one) DPI diphenyleneiodonium ERK extracellular signal-regulated kinase fMLF N-formyl-L-methionyl-L-leucyl-L-phenylalanine f-MMYALF N-formyl-Met-Met-Tyr-Ala-Leu-Phe FPR formyl peptide receptor GPCR G protein-couple receptor IC 50 The half maximal inhibitory concentration JNK c-Jun N-terminal kinase LDH lactate dehydrogenase LPS lipopolysaccharide m-3M3FBS 2,4,6-trimethyl-N-(meta-3-trifluoromethyl-phenyl)-benzenesulfonamide MAPK mitogen-activated protein kinase MMK1
Leu-Glu-Ser-Ile-Phe-Arg-Ser-Leu-Leu-Phe-Arg-Val-Met MPO myeloperoxidase NOX2 NADPH oxidase type 2 PKC protein kinase C PMA phorbol-12-myristate-13-acetate ROS reactive oxygen species WST-1 2-(4-iodophenyl)-3-(2,4-dinitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium oxidative stress accumulation [10] . Therefore, NOX2 is a promising therapeutic target for treating neutrophil-dominant inflammatory disorders.
Currently, only few drugs are used to inhibit neutrophil dysregulation during inflammation [11] [12] [13] . In a search for new anti-inflammatory agents, our laboratory established a platform for randomly screening small molecular compounds in activated human neutrophils. (Fig. 1A) , a newly synthesized derivative of benzo[f]indole-4,9-dione, was found to selectively inhibit O 2
•− generation but not elastase release in activated human neutrophils. In this study, we identified that CYR5099 acts as a NOX2 inhibitor and effectively inhibits the production of O 2 •− and ROS in activated human neutrophils. Therefore, we hypothesized that CYR5099 may have antiinflammatory effects via inhibiting oxidative stress. Arthritis is a common inflammatory disease characterized by increased ROS and proinflammatory cytokines that cause joint pain, swelling, and stiffness. Excessive ROS generation, particularly via NOX2, contributes to joint inflammation and articular cartilage degradation [3, 14] . Complete Freund's adjuvant (CFA) is a known potent inflammatory stimulus used in an experimental arthritis animal model [15] [16] [17] . CFA injection has been found to induce an increase of neutrophil infiltration in the arthritis synovium [17, 18] . The present study aimed to investigate the effects and molecular action of CYR5099 in human neutrophils and its protective effect in a murine CFA-induced paw inflammation model.
Materials and methods

Reagents
CYR5099 was synthesized by Professors Cherng-Chyi Tzeng and Yeh-Long Chen, Department of Medicinal and Applied Chemistry, Kaohsiung Medical University, Taiwan, and described in Supplementary Fig. 1 . Protease inhibitor cocktail tablet was obtained from Roche (Indianapolis, IN, USA). Dulbecco's Modified Eagle Medium (DMEM) and Hank's balanced salts solution (HBSS) were obtained from Gibco (Grand Island, NY, USA). Methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide and apocynin was obtained from Calbiochem (La Jolla, CA, USA). Interleukin-8 (IL-8) was obtained from ProSpec (East Brunswick, NJ, USA). 8-Amino-5-chloro-2,3-dihydro-7-phenyl-pyrido [3,4-d] pyridazine sodium salt (L-012) and Leu-Glu-Ser-Ile-Phe-Arg-Ser-Leu-LeuPhe-Arg-Val-Met (MMK-1) were obtained from Tocris Bioscience (Bristol, UK). Leukotriene B4 (LTB4) was purchased from Enzo Life Science (Farmingdale, NY, USA). 2-(4-Iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt (WST-1) was obtained from Dojindo (Kunamoto, Japan). Fluo-3 acetomethoxyester (Fluo-3/AM) was obtained from Molecular Probes (Eugene, OR, USA). Anti-rabbit Oregon Green 488, dihydroethidine (HE), Hoechst 33342, and 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate (DiI) were purchased from Invitrogen (Carlsbad, CA, USA). Xanthine were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antibodies of p38, phospho-p38 (Thr180/Tyr182), JNK, phospho-JNK (Thr183/Tyr185), Akt (pan), phospho-Akt (Ser473), ERK, phospho-ERK (Thr202/Tyr204), and HRP-linked anti-rabbit IgG were purchased from Cell Signaling (Beverly, MA, USA). Anti-Ly6G antibody was purchased from eBiosciences (San Diego, CA, USA 
, m-3M3FBS, phorbol 12-myristate 13-acetate (PMA), platelet activating factor (PAF), zymosan A, α-tocopherol, and xanthine oxidase (XO) were purchased from Sigma-Aldrich (St. Louis, MO, USA).
Isolation of human neutrophils
This study has been approved by the Institutional Review Board of Chang Gung Memorial Hospital (Registration number: IRB 100 1278C). Informed consent was written and obtained from healthy volunteer. Human neutrophils were isolated according to a standardized procedure: 3% (w/v) dextran sedimentation for 30 min, followed by gradient centrifugation in Ficoll-Hypaque and hypotonic lysis of erythrocytes. Cell viability of the purified neutrophils was determined using a hemocytometer and the trypan blue-positive neutrophils were determined. Experiments were performed using neutrophils that were > 98% viable. Neutrophils were suspended and maintained in cold HBSS buffer (pH 7.4) without calcium [19] .
Preparation of endothelial cell (ECs)
The murine brain microvascular ECs (bEnd.3) was obtained from the Bioresource Collection Center (Hsinchu, Taiwan). bEnd.3 were cultured in DMEM supplemented with 10% fetal bovine serum (FBS) containing antibiotics in a humidified atmosphere at 37°C with 5% CO 2 . bEnd.3 were passaged every 3 days at 1 × 10 5 cells/ml after cells reached confluence [20] . (15 μM)/CB (0.5 μg/ml), (E) LTB 4 (0.1 μM)/CB (0.5 μg/ml), (F) IL-8 (100 ng/ml)/CB (2 μg/ml), or (G) PAF (1 μM)/CB (0.5 μg/ml). Elastase release was measured spectrophotometrically at 450 nm. All data are expressed as mean ± S.E.M. (n = 4 or 6).
Measurement of O 2 •− generation
Ferricytochrome c was used to measure the amount of O 2
Human neutrophils (3 × 10 5 or 6 × 10 5 cells/ml) were preincubated with 0.5 mg/ml (40.4 μM) ferricytochrome c at 37°C, and then incubated with DMSO or CYR5099 for 5 min before activation by fMLF (0.1 μM), MMK1 (0.3 μM), f-MMYALF (0.3 μM), m-3M3FBS (15 μM) or PMA (10 nM). CB (1 μg/ml) was added to priming neutrophils before stimulators, except for PMA. CB converted neutrophils from phagocytic to secretory cells for facilitating respiratory burst and degranulation via disaggregation of intracellular actin network [22] . The absorbance was monitored continuously using a spectrophotometer at 550 nm. Luminal or isoluminol enhanced chemiluminescence was used to assay total ROS or extracellular ROS, respectively [19] . Human neutrophils (7 × 10 5 cells/ml) were preincubated with 37.5 μM luminol or isoluminol in the presence of 6 U/ml horseradish peroxidase at 37°C, and then incubated with DMSO or CYR5099 for 5 min before activation.
Analysis of elastase release
Human neutrophils (6 × 10 5 or 1 × 10 6 cells/ml) were pre-incubated with methoxysuccinyl-Ala-Ala-Pro-Val-p-nitroanilide (elastase substrate, 100 μM) at 37°C, and then treated with DMSO or CYR5099 for 5 min before activation by fMLF (0.1 μM), f-MMYALF (0.3 μM), MMK1 (0.3 μM), m-3M3FBS (15 μM), LTB 4 (0.1 μM), IL-8 (100 ng/ml) or PAF (1 μM) in the presence of CB (0.5 or 2 μg/ml). The absorbance was monitored continuously using a spectrophotometer at 405 nm [23] .
Detection of cytotoxicity
Lactate dehydrogenase (LDH) assay kit (Promega, Madison, WI, USA) was used to determine the cytotoxicity. Human neutrophils were treated with DMSO or CYR5099 for 15 min at 37°C. Cell-free supernatants were collected and LDH was measured [24] . and then activated PMA (10 nM). Cells were fixed with 4% paraformaldehyde and stained with anti-p47 phox antibody, DiI, and Hochst 33342. p47 phox , DiI, and Hoechst 33342 staining are shown in green, red, and blue, respectively. Co-distribution (orange) was determined by merging the green and red images. Scale bar: 2 μm. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
O 2
•− and free radical scavenging assay
The scavenging effects of CYR5099 on O 2 •− or free radicals were determined in cell-free xanthine/xanthine oxidase (XO), DPPH, or ABTS assays [25] .
NOX2 activity assay
Cellular NOX2 activity was measured in human neutrophils. Neutrophils (6 × 10 5 cells/ml) were preincubated with PMA (10 nM) at 37°C for 5 min, and treated with DMSO, CYR5099 or NOX2 inhibitors (apocynin and DPI) for 5 min. O 2 •− generation by NOX2 was assayed by the addition of ferricytochrome c (0.5 mg/ml). Subcellular NOX2 activity was also determined. Neutrophils were preincubated with protease inhibitor cocktail tablet (1/1000; Roche, Indianapolis, IN, USA) for 30 min at 4°C, and then cells were sonicated in NOX2 assay buffer (pH 7.3; 100 mM KCl, 10 mM PIPES, 3 mM NaCl, 1 mM EGTA, 3.5 mM MgCl 2 , and 1 mM ATP). Nonruptured neutrophils were removed by centrifugation at 300×g for 5 min. The cytosolic and membrane fractions were isolated by centrifugation at 14,000×g for 30 min at 4°C. The cytosol fraction and membrane fraction were mixed in reaction buffer (10 mM NaH 2 PO 4 /Na 2 HPO 4 .12H 2 O, 2.7 mM KCl, 138 mM NaCl, 2 mM MgCl 2 , 2 μM GTPγS, and 0.5 mg/ml ferricytochrome c; pH 7.4) at 30°C. NOX2 was activated with the addition of 100 μM sodium dodecyl sulfate (SDS) before the addition of DMSO, CYR5099, apocynin, or DPI. The absorbance was monitored continuously using a spectrophotometer at 550 nm [21] .
Measurement of intracellular calcium concentration ([Ca
] i )
Human neutrophils (3 × 10 6 cells/ml) were labeled with fluo-3/AM (2 μM) at 37°C for 35 min. Labeled neutrophils were preincubated with DMSO or CYR5099 for 5 min, and then activated by fMLF (0.
The changes of fluorescence were monitored continuously using a spectrofluorometer [26] .
Immunoblotting analysis
Neutrophils were treated with DMSO or CYR5099 for 5 min, and then activated with fMLF (0.1 μM)/CB (0.5 μg/ml) for 25 s. The reaction was stopped by the addition of sample buffer (62.5 mM pH 6.8 Tris-HCl, 4% sodium dodecyl sulfate (SDS), 5% β-mercaptoethanol, 0.0125% bromophenol blue, and 8.75% glycerol) at 100°C for 15 min. Wholecell lysates were obtained by centrifugation at 14,000×g for 20 min at 4°C. Phosphorylation of MAPKs and Akt was assayed by immunoblotting with the corresponding rabbit antibodies (1:2000) and HRP-linked anti-rabbit IgG antibodies (1:10000). The phosphorylated and total proteins were identified using enhanced chemiluminescence kits, and evaluated using a densitometer (UVP, Upland, CA, USA) [27] .
Analysis of CD11b expression
Human neutrophils were pretreated with DMSO or CYR5099 for Fig. 8 . CYR5099 inhibits NOX2 activity. A mixture of cytosolic and membrane fractions from neutrophils was pretreated with SDS (100 μM) for 2 min, and then incubated with (A) CYR5099 (3, 10, and 15 μM) or (B) DPI (0.3 and 1 μM) and apocynin (300 μM). The reaction was initiated by adding NADPH (160 μM). All data are expressed as mean ± S.E.M. (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001 compared with control. 
Neutrophil adhesion detection
Human neutrophils were pre-incubated with Hoechst 33342 for 10 min and then centrifuged at 200×g for 8 min to discard the supernatant. Hoechst 33342-labeled human neutrophils were treated with DMSO or CYR5099 for 5 min and then activated by fMLF (0.1 μM)/CB (0.5 μg/ml) for 10 min. Afterwards, cells were co-cultured with LPS (2 μg/ml)-pretreated bEnd.3 cells for 15 min. Non-adherent neutrophils were removed by gentle washing with HBSS and neutrophils adhered to bEnd.3 were counted in 6 fields by microscopy [20, 28] .
Immunofluorescence staining
Human neutrophils were incubated on fibrinogen (1 mg/ml)-coated glass slides at 37°C for 30 min, and then treated with DMSO or CYR5099 for 5 min before activating by PMA (10 nM) for an additional 5 min. Cells were fixed with 4% paraformaldehyde, washed three times with PBS, and permeabilized with 0.05% (w/v) Triton X-100. Afterwards, cells were soaked three times with 0.15 M glycine/PBS, and blocked with 5% goat serum for 1 h at 4°C. Cells were incubated with anti-p47 phox antibody (1:500) overnight at 4°C, followed by incubation with secondary Oregon Green 488-conjugated anti-rabbit IgG antibody (1:1000) for 1 h. Cells were then washed with 0.15 M glycine/PBS and stained with Hoechst 33342 (1 ng/ml) and DiI (1 ng/ml) for 10 min at room temperature. Images were collected by Zeiss LSM 510 Meta confocal microscopy [24] . 
Protein preparation and molecular docking
The crystal structure of p67 phox and p40 phox were obtained from the Protein Data Bank (PDB; accession code: 1E96 and 1H6H, respectively). The remodeling structure of human gp91 phox was superimposed from the C-terminal human gp91phox (PDB 3A1F) and FAD-binding region of C. stagnale NADPH oxidase (PDB 5O0X) using MODELLER ( Supplementary Fig. 2 ). All structures were prepared to fix commonly problems and protonated at pH 7.4. The 2D structure of CYR5099 was sketched by BIOVIA draw and transfer to 3D coordinates using Catalyst. CYR5099 was docked to gp91 phox , p67 phox , or p40 phox protein using CDOCKER program (Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release 2019, San Diego: Dassault Systèmes, 2019). The conformational differences between crystal and calculated substrates were evaluated by RMSD value for each NOX2 subunit. CDOCKER interaction energy and binding energy (ΔG bind ) were employed to prioritize the potential target of CYR5099.
Complete Freund's adjuvant (CFA)-induced paw inflammation
C57BL/6 male mice (7-8 weeks) were housed in an air-conditioned room with 12 h light-dark cycle, and animal studies were conducted according to the guidelines and protocol approved by Institutional Animal Care and Use Committee at Chang Gung University, Taiwan (IACUC approval No. CGU14-150). Mice were injected subcutaneously with carprofen (5 mg/kg) as analgesia and then intraperitoneally with CYR5099 (10 or 25 mg/kg body weight) or an equal volume of 0.9% saline under anesthesia (Isoflurane). After 1 h, paw inflammation was induced by intraplantar injection of CFA (1.5 mg/kg body weight in right-rear foot) or 0.9% saline (left-rear foot; as control). The change in paw thickness (nm) was determined before (baseline) and after CFA/ saline injection at the indicated times. After injection of CFA for 4 h, L-012 (25 mg/kg body weight) was intraperitoneally administered. ROS production was determined using a Xenogen IVIS100 imaging system (PerkinElmer, Waltham, MA, USA) under anesthesia (30 mg/kg Zoletil 50 and 6 mg/kg xylazine) [17, 29] . CO 2 euthanasia was used to stop the experiments. The hind paws were removed, fixed using 10% neutral buffered formalin, and embedded in paraffin blocks before cutting into 5-μm-thick sections. The staining of hematoxylin and eosin (H&E) and immunohistochemistry (Ly6G and MPO) was performed as previously described [17] . 
Statistical analysis
Statistical analyses were performed with SigmaPlot 8.02 (Systat Software, San Jose, CA, USA) and significance was calculated using Student's t-test. All data were normally distributed and expressed as the mean ± standard error of the mean (S.E.M.). A value of p < 0.05 was considered statistically significant.
Results
CYR5099 significantly decreases O 2
•− and ROS production, but not elastase release, in activated human neutrophils
To examine the anti-inflammatory effects of CYR5099 in human neutrophils, the O 2
•− generation and ROS production were analyzed. •− generation in fMLF-activated human neutrophils ( Supplementary Fig. 3 ). In addition, luminal and isoluminol-enhanced chemiluminescence assays indicated that CYR5099 significantly decreased total and extracellular ROS generation induced by fMLF and PMA (Fig. 2) . CYR5099 also restricted total ROS production in human neutrophils stimulated by zymosan A, a pathogen prepared from S. cerevisiae ( Supplementary Fig. 4 ). These results indicated that CYR5099 has anti-inflammatory effects through inhibiting human neutrophil oxidative stress. CYR5099 did not induce LDH release in human neutrophils, even in the presence of activators (fMLF or PMA), and it did not have O 2
•− and free radicals-scavenging activity in cellfree xanthine/xanthine oxidase, DPPH, or ABTS assays ( Fig. 3 and Supplementary Fig. 5 ), ruling out the anti-inflammatory effects were due to cytotoxicity or direct O 2 •− -scavenging.
Elastase release is an important indicator of neutrophil degranulation. To determine whether CYR5099 has inhibitory effect on degranulation, elastase release was monitored. CYR5099 did not affect elastase release in human neutrophils activated by fMLF, f-MMYALF, MMK1, m-3M3FBS, LTB 4 , IL-8, and PAF (Fig. 4). 
CYR5099 inhibits NOX2 activity
NOX2 activation is dependent on phosphorylation of p47 phox , a cytosolic component of the enzyme. p47 phox phosphorylation stimulates translocation of the cytosolic components to the membranes to induce NOX2 activation [30, 31] . Our result indicated that CYR5099 failed to alter PMA-induced p47 phox phosphorylation and translocation to membrane in human neutrophils ( Fig. 5 and Supplementary Fig. 6 ), ruling out that the inhibition of O 2 •− and ROS production by CYR5099
was through regulating NOX2 upstream pathways. To further examine the inhibitory effect of CYR5099 on NOX2, cellular and subcellular NOX2 activities were measured. In the cellular system, CYR5099 inhibited NOX2-mediated O 2
•− generation in PMApreactivated human neutrophils (Fig. 6A) . DPI and apocynin are two well-studied inhibitor of NOX2 [32] . In this study, DPI (0.3 μM) and apocynin (300 μM) were used as positive controls and showed significant inhibition (Fig. 6B) . Furthermore, DPI (3-300 nM) and apocynin (3-300 μM) inhibited O 2 •− production, but not elastase release, in fMLF-activated human neutrophils (Fig. 7) . We suggest that CYR5099 may act as an inhibitor of NOX2. To identify this hypothesis, NOX2 activity assay was performed in subcellular experiments. Noticeably, our data showed that CYR5099 and DPI reduced the NOX2 activity in SDS-reconstituted subcellular assay (Fig. 8) . Therefore, CYR5099 is a new NOX2 inhibitor and can inhibit respiratory burst in human neutrophils. Interestingly, apocynin did not significantly inhibit subcellular NOX2 activity. A possible explanation is that apocynin is a prodrug. Apocynin requires MPO and H 2 O 2 to form an activate apocynin radical and dimer [33] [34] [35] [36] .
NOX2 is comprised of gp91 phox (NOX2), p22  phox , p47  phox , p67   phox   ,  p40 phox , and Rac2 in neutrophils [5, 6] . The molecular docking of CYR5099 with NOX2 subunits was performed to determine how CYR5099 blocked the NOX2 activity. CDOCKER interaction energy and CHARMm forcefield were employed for the molecular dynamics scheme to dock ligands into a protein binding site. (Fig. 9) . Based on molecular docking results, we suggest that CYR5099 may selectively target gp91 phox , a specific subunit of NOX2. To further examine the selectivity of CYR5099, we detected the ROS generation in HT-29 cells, which highly expressed NOX1 but not other NOX types [37, 38] . DPI (0.3 and 3 μM) and apocynin (10 and 30 μM) but not CYR5099 (5 and 10 μM) apparently inhibited NOX1-dependent ROS generation (Supplementary Fig. 7 ). Using neutrophil-like differentiated HL-60 (dHL-60) cells [39] , both CYR5099 (5 and 10 μM) and p47 phox knockdown clearly inhibited the PMA-induced superoxide anion generation. Additionally, CYR5099 (5 and 10 μM) failed to further repress the superoxide anion generation in p47 phox -knockdown dHL-60 cells (Supplementary Fig. 8 ), suggesting that CYR5099 may be a selective inhibitor of NOX2. (Fig. 10) . Additionally, MAPKs and Akt play important roles in neutrophil inflammatory responses [17, 19] . Treatment with fMLF caused rapid activation of p38 MAPK, ERK, JNK, and Akt in human neutrophils. CYR5099 did not affect the phosphorylation of p38 MAPK, JNK, and Akt. However, CYR5099 at high concentration of 10 μM had a minor inhibitory effect on ERK phosphorylation (Fig. 11) .
CYR5099 inhibits neutrophil CD11b expression and adhesion to ECs
CD11b/CD18 is an important integrin for neutrophil adhesion to endothelium [40] . Treatment with fMLF and PMA induced increases in CD11b expression in human neutrophils. CYR5099 significantly reduced fMLF and PMA-induced CD11b expression ( Fig. 12A and B) . Likewise, fMLF-induced human neutrophil adhesion to bEnd.3 was inhibited by CYR5099 (Fig. 12C and D) . Both DPI and apocynin also showed significant inhibitory effects on CD11b expression (Fig. 13) , suggesting that NOX2-mediated ROS may involve in integrin expression.
CYR5099 ameliorates CFA-induced arthritis inflammation
The in vivo effect of CYR5099 was investigated in CFA-induced arthritis inflammation in mice. CFA treatment caused an increase in ROS generation and edema in mouse paw. The histology of paw sections showed that CFA induced neutrophil (Ly6G + and MPO + ) infiltration and interstitial edema (Fig. 14) . The intraperitoneal administration of CYR5099 (10 or 25 mg/kg body weight) resulted in a significant reduction of CFA-induced paw ROS production, neutrophil infiltration, and edema (Fig. 14) .
Discussion
NOX2, a respiratory burst oxidase, generates O 2
•− in activated neutrophils [41, 42] . Dysregulation of NOX2 plays a significant role in the development of neutrophil-dominated inflammatory diseases [3] . Therefore, NOX2 is a promising therapeutic target for oxidative stressrelated inflammatory diseases. In the present study, we demonstrated that CYR5099, a new small molecule compound derived from benzo[f] indole-4,9-dione, reduces O 2 •− production, ROS generation, and CD11b integrin expression in activated human neutrophils via inhibiting NOX2 activity. CYR5099 also showed therapeutic potential against CFA-induced inflammatory arthritis injury. Neutrophils are essential innate immune cells. Neutrophils generate ROS by NOX2 which can kill pathogen [41] [42] [43] . However, large amounts of ROS can cause tissue damage and lead to inflammatory diseases, such as arthritis, psoriasis, and systemic lupus erythematosus [3, [44] [45] [46] . In this study, we confirmed the anti-inflammatory properties of CYR5099 on reducing oxidative stress caused by activated human neutrophils. CYR5099 does-dependently attenuated O 2
• to induce respiratory burst in neutrophils [52] . CYR5099 did not inhibit the phosphorylation of p38, JNK, and Akt. However, CYR5099 inhibited ERK phosphorylation by 31.6% in fMLF-activated human neutrophils. Previous studies have shown that ROS can induced ERK phosphorylation [53] [54] [55] . Therefore, reduction of ERK phosphorylation by CYR5099 may result from its inhibitory effect on ROS formation in activated human neutrophils. Since CYR5099 did not block NOX2 upstream signaling pathways, we propose that CYR5099 is a direct NOX2 inhibitor. Consistent with our hypothesis, CYR5099 revealed significant inhibitory effects on NOX2-mediated O 2
•− generation in PMA-preactivated human neutrophils and SDS-reconstructed subcellular system. p47 phox phosphorylation plays a critical role in NOX2 activation [56] [57] [58] . The immunofluorescence and immunoblotting assay indicated that CYR5099 did not influence p47 phox membrane translocation in activated human neutrophils. Apocynin and DPI, two well-known inhibitors of NOX2 [32] , inhibited NOX2-mediated O 2
•− generation in activated human neutrophils. ROS can stimulate CD11b expression, which mediates neutrophil adhesion and migration [20, 59] . Additionally, angiotensin II-induced T cells tissue homing is ameliorated in p47 phox -deficient mice [60] , suggesting that targeting NOX2 prevents immune cell infiltration. CYR5099 significantly inhibited CD11b expression in fMLF-or PMAactivated human neutrophils. The NOX2 inhibitors, DPI and apocynin, showed the same effects. CYR5099 is a NOX2 inhibitor that functions similar to DPI. The prodrug apocynin requires MPO and H 2 O 2 to form an activate NOX2 inhibitor [33] [34] [35] [36] . We also noted that apocynin failed to inhibit NOX2-mediated O 2 •− generation in SDS-reconstructed subcellular system. Arthritis is a common health problem resulting from joint inflammation. The pathogenesis of arthritis involves ROS formation, immune cell infiltration, and synovial hyperplasia [61, 62] . Previous studies have shown that the severity of arthritis correlates with ROS level and NOX2 overexpression in mice with hypoxic inflammatory arthritis [8] . Excessive ROS generation is also associated with synovial membrane inflammation, and NOX2-mediated ROS production contributes to osteoarthritic joint inflammation and articular cartilage degradation [63] . Our results showed that CYR5099 significantly reduced ROS level, neutrophil infiltration, and edema in CFA-induced paw inflammation in mice. Therefore, targeting NOX2 may have therapeutic potential in arthritis inflammation.
Direct inhibition of NOX2 activity could be dangerous. Chronic granulomatous disease patients, who have defects in O 2
•− -generating NOX2, suffer from increased susceptibility for bacterial and fungal infections and also other disease conditions such as Crohn's disease and pancolitis [64, 65] . Therefore, people should pay attention to the clinical use of NOX2 inhibitors. In this study, an acute inflammatory arthritis mouse model was used to examine the preclinical effect of CYR5099. Our results suggest that CYR5099 may be a lead compound for the development of NOX2 inhibitor to treat neutrophil-dominant acute oxidative inflammatory disorders.
Conclusion
In summary, this is the first time to identify a novel small molecule CYR5099 to target NOX2 for restricting neutrophilic inflammation, including O 2
•− production, ROS generation, CD11b integrin expression, and cell adhesion. Our in vivo study demonstrates that CYR5099 ameliorates neutrophil-mediated inflammatory arthritis. CYR5099 can be a lead compound for the development of NOX2 inhibitor to treat neutrophil-mediated inflammatory diseases.
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